GlaxoSmithKline agrees to $75 million settlement in drug patent suit - - Tulsa, OK - News, Weather, Video and Sports - |

GlaxoSmithKline agrees to $75 million settlement in drug patent suit

BOSTON (AP) _ GlaxoSmithKline Corp. has agreed to pay a $75 million settlement over a lawsuit that alleged the company used illegal tactics to maintain its patent on an anti-inflammatory drug and keep a cheaper generic version off the market.

The agreement will create a $25 million pool to reimburse individuals for overcharges on the drug Relafen, and a $50 million pool for third-party payers, such as health insurers.

The settlement, which must be approved by a federal judge Boston, springs from a lawsuit brought last year by consumer group Prescription Access Litigation, whose director Alex Sugarman-Brozan called the deal ``a significant victory for consumers.''

``Cases such as this put the drug industry on notice that consumers are fed up with the manipulation of drug prices,'' he said.

GlaxoSmithKline did not admit wrongdoing in the proposed settlement.

PAL, a nationwide coalition of 93 consumer groups in 34 states, sued GlaxoSmithKline on behalf of two individuals and two consumer organizations, Health Care For All and Wisconsin Citizen Action.
Powered by Frankly
News On 6
303 N. Boston Ave.
Tulsa, OK 74103 is proud to provide Oklahomans with timely and relevant news and information, sharing the stories, pictures and loves of Oklahomans across our great state.
All content © Copyright 2000 - 2018 KOTV. Oklahoma Traveler™ is a registered trademark of Griffin Communications. All Rights Reserved.
For more information on this site, please read our Privacy Policy, and Terms of Service, and Ad Choices.